Skip to main content
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ATNM ISIN · US00507W2061 LEI · 549300LCY1NZSXCQDT45 US Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2008-08-14 Interim / Quarterly Rep…
Country US United States of America
Listing US ATNM

About Actinium Pharmaceuticals, Inc.

https://www.actiniumpharma.com/

Actinium Pharmaceuticals, Inc. is a clinical-stage company focused on developing targeted radiotherapies for patients with cancers lacking effective treatment options. The company's platform utilizes potent radioisotopes, such as the alpha-emitter Actinium-225, conjugated to monoclonal antibodies to precisely deliver radiation to cancer cells. Its clinical pipeline addresses hematologic malignancies and solid tumors. Key programs include Iomab-B, a targeted conditioning agent for bone marrow transplant in patients with relapsed or refractory Acute Myeloid Leukemia (AML), and Actimab-A, a CD33-targeting therapy for AML. The company is also advancing ATNM-400, a novel non-PSMA therapeutic for prostate cancer, and developing its proprietary Actinium-225 manufacturing technology and infrastructure.

Recent filings

Filing Released Lang Actions
JUNE 30, 2008 10-Q
Interim / Quarterly Report H1 2008
2008-08-14 English
CACTUS VENTURES, INC 10Q 3.31.2008
Interim / Quarterly Report Q1 2008
2008-05-07 English
CACTUS VENTURES, INC. 10KSB/A 12.31.07
Annual Report Classification · 100% confidence The document is titled 'Form 10-KSB/A' and is described as an 'ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934' for the fiscal year ended December 31, 2007. It contains detailed business descriptions, legal proceedings, stockholder matters, and other comprehensive information typical of an annual report. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of detailed sections such as business description, legal proceedings, and stockholder matters confirms it is a full annual report filing. Therefore, the appropriate classification is Annual Report (10-K).
2008-04-04 English
CACTUS VENTURES, INC. 10KSB 12.31.2007
Annual Report Classification · 100% confidence The document is titled 'Form 10-KSB' and is described as an 'ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934' for the fiscal year ended December 31, 2007. It contains detailed business descriptions, legal proceedings, stockholder matters, and financial information typical of an annual report. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of SEC form identifiers and the fiscal year end date further confirm this is a full annual report filing. Therefore, the document is classified as an Annual Report (10-K).
2008-02-12 English
CACTUS VENTURES, INC. 10 QSB 9.30.2007
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FORM 10-QSB' and is explicitly described as a 'Quarterly Report' for the period ended September 30, 2007. It contains detailed unaudited financial statements including balance sheets, statements of operations, shareholders' deficit, cash flows, and notes to the condensed financial statements. The presence of these substantive financial data and management discussion confirms it is a quarterly financial report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2007-11-13 English
CACTUS VENTURES, INC. DEFINITIVE 14C INFORMATION 11.13.2007
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14C Information Statement filed with the SEC, specifically titled "Definitive 14C Information" for Cactus Ventures, Inc. It discusses shareholder actions taken without a meeting via written consent, including a reverse stock split and an increase in authorized capital stock. The content focuses on proxy solicitation and shareholder voting matters, including detailed explanations of the proposed corporate actions and shareholder ownership. There is no financial data, earnings information, or audit content. The document is a proxy-related filing providing information to shareholders to solicit their consent or votes on corporate actions. According to the filing definitions, Schedule 14C filings are classified as Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and detailed content confirm it is the information statement itself, not just an announcement or a brief notice. Therefore, the correct classification is PSI with high confidence.
2007-11-13 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.